Mobile

A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, LONG-TERM EXTENSION STUDY TO DETERMINE THE SAFETY, TOLERABILITY, AND PRELIMINARY LONG TERM EFFICACY OF LECOZOTAN (SRA-333) SR IN PATIENTS WITH MILD TO MODERATE...

Update Il y a 4 ans
Reference: EUCTR2005-001476-13

A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, LONG-TERM EXTENSION STUDY TO DETERMINE THE SAFETY, TOLERABILITY, AND PRELIMINARY LONG TERM EFFICACY OF LECOZOTAN (SRA-333) SR IN PATIENTS WITH MILD TO MODERATE ALZHEIMER’S DISEASE

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

Primary: To evaluate the safety and tolerability of long-term therapy with three dose levels (2, 5, 10 mg daily) of Lecozotan (SRA-333) SR administered to patients with mild to moderate Alzheimer’s Disease who have completed Week 12 evaluations of study 3098B1-201-EU [EudraCT No. 2005-001475-35].

Inclusion criteria

  • Alzheimer's disease

Links